Real-world use of oral semaglutide in adults with type 2 diabetes.

IF 1.1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Danish medical journal Pub Date : 2026-06-16 DOI:10.61409/A06250520

Klaus Roslind, Ulrik Bodholdt, Tina Damgaard, Christian Jensen

{"title":"Real-world use of oral semaglutide in adults with type 2 diabetes.","authors":"Klaus Roslind, Ulrik Bodholdt, Tina Damgaard, Christian Jensen","doi":"10.61409/A06250520","DOIUrl":null,"url":null,"abstract":"Introduction: PIONEER REAL Denmark assessed changes in HbA1c, body weight and treatment satisfaction with once-daily oral semaglutide in adults with type 2 diabetes.Methods: In this multicentre, prospective, open-label, non-interventional study, participants initiated oral semaglutide in routine clinical practice and were followed up for 34-44 weeks. The primary endpoint was change in HbA1c from baseline to the end of study (EOS). Secondary endpoints assessed at EOS included change in body weight (BW), proportion of participants reaching HbA1c less-than 7% and treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire status/change (DTSQs/DTSQc).Results: In total, 96 participants from a primary care setting were included (median age: 63.5 years, HbA1c: 7.6% (60.0 mmol/mol), BW: 97.4 kg). Estimated changes from baseline to EOS in HbA1c (n = 96) and BW (n = 86) were -0.9 percentage points (9.9 mmol/mol) (95% CI: -1.20; -0.61 percentage points) and -4.4 (95% CI: -5.44; -3.41) kg, respectively. At baseline, 28.1% of participants had HbA1c less-than 7.0% (less-than 53 mmol/mol); at EOS, 66.7% of participants had HbA1c less-than 7.0% (53 mmol/mol). Improvements in treatment satisfaction were observed in DTSQs (1.9 points) and DTSQc (10.5 points) scores. No new safety signals were identified for oral semaglutide.Conclusions: In PIONEER REAL Denmark, participants treated with oral semaglutide in a primary care setting experienced reductions in HbA1c and BW.Funding: This study was sponsored by Novo Nordisk A/S.Trial registration: Clinicaltrials: gov (NCT04537637).","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"73 7","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2026-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A06250520","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: PIONEER REAL Denmark assessed changes in HbA1c, body weight and treatment satisfaction with once-daily oral semaglutide in adults with type 2 diabetes.

Methods: In this multicentre, prospective, open-label, non-interventional study, participants initiated oral semaglutide in routine clinical practice and were followed up for 34-44 weeks. The primary endpoint was change in HbA1c from baseline to the end of study (EOS). Secondary endpoints assessed at EOS included change in body weight (BW), proportion of participants reaching HbA1c less-than 7% and treatment satisfaction using Diabetes Treatment Satisfaction Questionnaire status/change (DTSQs/DTSQc).

Results: In total, 96 participants from a primary care setting were included (median age: 63.5 years, HbA1c: 7.6% (60.0 mmol/mol), BW: 97.4 kg). Estimated changes from baseline to EOS in HbA1c (n = 96) and BW (n = 86) were -0.9 percentage points (9.9 mmol/mol) (95% CI: -1.20; -0.61 percentage points) and -4.4 (95% CI: -5.44; -3.41) kg, respectively. At baseline, 28.1% of participants had HbA1c less-than 7.0% (less-than 53 mmol/mol); at EOS, 66.7% of participants had HbA1c less-than 7.0% (53 mmol/mol). Improvements in treatment satisfaction were observed in DTSQs (1.9 points) and DTSQc (10.5 points) scores. No new safety signals were identified for oral semaglutide.

Conclusions: In PIONEER REAL Denmark, participants treated with oral semaglutide in a primary care setting experienced reductions in HbA1c and BW.

Funding: This study was sponsored by Novo Nordisk A/S.

Trial registration:

Clinicaltrials: gov (NCT04537637).

查看原文本刊更多论文

口服西马鲁肽在成人2型糖尿病患者中的实际应用。

PIONEER REAL丹麦评估成人2型糖尿病患者每日一次口服西马鲁肽后HbA1c、体重和治疗满意度的变化。方法：在这项多中心、前瞻性、开放标签、非介入性研究中，参与者在常规临床实践中开始口服西马鲁肽，随访34-44周。主要终点是HbA1c从基线到研究结束（EOS）的变化。EOS评估的次要终点包括体重变化（BW）， HbA1c低于7%的参与者比例以及使用糖尿病治疗满意度问卷状态/变化（DTSQs/DTSQc）的治疗满意度。结果：共纳入96名来自初级保健机构的参与者（中位年龄：63.5岁，HbA1c: 7.6% (60.0 mmol/mol)，体重：97.4 kg）。HbA1c （n = 96）和BW （n = 86）从基线到EOS的估计变化分别为-0.9个百分点（9.9 mmol/mol）（95% CI: -1.20; -0.61个百分点）和-4.4 (95% CI: -5.44; -3.41) kg。在基线时，28.1%的参与者HbA1c低于7.0%（低于53 mmol/mol）；在EOS， 66.7%的参与者HbA1c低于7.0% （53 mmol/mol）。治疗满意度在DTSQs（1.9分）和DTSQc（10.5分）评分上均有改善。未发现口服西马鲁肽新的安全性信号。结论：在PIONEER REAL丹麦，在初级保健机构接受口服西马鲁肽治疗的参与者HbA1c和BW降低。资助：本研究由诺和诺德公司赞助。试验注册：Clinicaltrials: gov （NCT04537637）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Danish medical journal MEDICINE, GENERAL & INTERNAL-

CiteScore

2.30

自引率

6.20%

发文量

审稿时长

3-8 weeks

期刊介绍： The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content. DMJ will publish the following articles: • Original articles • Protocol articles from large randomized clinical trials • Systematic reviews and meta-analyses • PhD theses from Danish faculties of health sciences • DMSc theses from Danish faculties of health sciences.